Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota-Reference-Cited by-同舟云学术

Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lomeli Barbara K.¹,Galbraith Hal¹,Schettler Jared¹,Saviolakis George A.²,El-Amin Wael²,Osborn Blaire³,Ravel Jacques⁴⁵^ORCID,Hazleton Keith⁶,Lozupone Catherine A.⁷,Evans Ronald J.⁸,Bell Stacie J.⁸,Ochsner Urs A.⁸,Jarvis Thale C.⁸,Baqar Shahida³,Janjic Nebojsa⁸

Affiliation:

1. Quintiles Phase One Services, Overland Park, Kansas, USA

2. DynPort Vaccine Company LLC, Frederick, Maryland, USA

3. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

4. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA

5. Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA

6. Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

7. Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

8. Crestone, Inc., Boulder, Colorado, USA

Abstract

CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01395-19

Reference48 articles.

1. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

2. CDC. 2015. Nearly half a million Americans suffered from Clostridium difficile infections in a single year. https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html.

3. Survey of Health Care–Associated Infections

4. Burden ofClostridium difficileInfection in the United States

5. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17

2. Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies;Journal of Pharmacy Practice;2024-05-13

3. UPLC/Q‐TOF–MS‐based metabolomics and molecular docking analysis of Bifidobacterium adolescentis exposure to levofloxacin;Biomedical Chromatography;2024-04-29

4. Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation;International Journal of Biological Macromolecules;2024-04

5. Biochemical and structural characterization of chlorhexidine as an ATP-assisted inhibitor against type 1 methionyl-tRNA synthetase from Gram-positive bacteria;European Journal of Medicinal Chemistry;2024-03